Successful treatment of psoriatic onycho-pachydermo periostitis (POPP) with adalimumab

T. Bongartz, P. Härle, S. Friedrich, S. Karrer, T. Vogt, A. Seitz, U. Müller-Ladner

Research output: Contribution to journalArticlepeer-review

38 Scopus citations


Psoriatic onycho-pachydermo periostitis (POPP) is recognized as a rare subset of psoriatic arthritis, characterized by psoriatic onychodystrophy, connective tissue thickening above the distal phalanx, and a periosteal reaction. Therapy for this rare disease is based on treatments used for psoriatic arthritis, but traditional disease-modifying antirheumatic drugs, such as sulfasalazine and methotrexate, have shown inconsistent and unsatisfactory results. We report herein a successful therapeutic approach for POPP using the fully human anti-tumor necrosis factor (TNF) antibody adalimumab in a 42-year-old male patient. After 4 months of anti-TNF treatment, a remarkable normalization of the clinical appearance was achieved and magnetic resonance imaging showed complete resolution of the initial inflammatory lesions. Therefore, we consider a TNF-blocking strategy as promising for treatment of POPP.

Original languageEnglish (US)
Pages (from-to)280-282
Number of pages3
JournalArthritis and rheumatism
Issue number1
StatePublished - Jan 1 2005

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)


Dive into the research topics of 'Successful treatment of psoriatic onycho-pachydermo periostitis (POPP) with adalimumab'. Together they form a unique fingerprint.

Cite this